Leerink Partnrs Forecasts Weaker Earnings for Beta Bionics

Beta Bionics, Inc. (NASDAQ:BBNX) – Leerink Partnrs reduced their Q1 2025 earnings per share estimates for Beta Bionics in a note issued to investors on Wednesday, March 26th. Leerink Partnrs analyst M. Kratky now anticipates that the company will post earnings per share of ($0.51) for the quarter, down from their prior estimate of ($0.50). Leerink Partnrs currently has a “Strong-Buy” rating on the stock. Leerink Partnrs also issued estimates for Beta Bionics’ Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.83) EPS and FY2027 earnings at ($2.27) EPS.

Other equities research analysts have also issued research reports about the stock. Bank of America started coverage on shares of Beta Bionics in a report on Monday, February 24th. They issued a “buy” rating on the stock. Lake Street Capital initiated coverage on Beta Bionics in a research note on Monday, February 24th. They issued a “buy” rating and a $30.00 target price on the stock. Piper Sandler started coverage on Beta Bionics in a research report on Monday, February 24th. They set an “overweight” rating and a $26.00 price target for the company. Stifel Nicolaus started coverage on Beta Bionics in a research report on Monday, February 24th. They issued a “buy” rating and a $25.00 price objective on the stock. Finally, LADENBURG THALM/SH SH started coverage on Beta Bionics in a report on Thursday, February 20th. They set a “neutral” rating and a $20.00 target price for the company. Three analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $24.83.

Beta Bionics Trading Down 7.6 %

Shares of NASDAQ BBNX opened at $11.71 on Friday. The business has a fifty day moving average price of $18.76. Beta Bionics has a 52 week low of $11.43 and a 52 week high of $24.50.

Beta Bionics (NASDAQ:BBNX) last posted its quarterly earnings results on Tuesday, March 25th. The company reported ($1.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($1.40). The company had revenue of $20.44 million during the quarter, compared to analyst estimates of $20.01 million.

Insider Activity at Beta Bionics

In other news, insider Mike Mensinger acquired 33,350 shares of the stock in a transaction on Friday, January 31st. The stock was acquired at an average price of $17.00 per share, with a total value of $566,950.00. Following the completion of the transaction, the insider now owns 59,019 shares of the company’s stock, valued at $1,003,323. This represents a 129.92 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Hadley Harbor Aggre Wellington bought 1,000,000 shares of Beta Bionics stock in a transaction dated Friday, January 31st. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $17,000,000.00. Following the completion of the transaction, the insider now directly owns 3,901,599 shares in the company, valued at approximately $66,327,183. This trade represents a 34.46 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

About Beta Bionics

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.